
    
      Multicenter, double-blind randomized trial to evaluate the efficacy of low dose colchicine
      (0.5mg once daily for 2 years) to reduce the incidence of subsequent overall mortality, new
      acute coronary syndromes, and ischemic stroke in patients admitted for an acute coronary
      syndrome.
    
  